---
title: "12 Health Care Stocks Moving In Friday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297357269.md"
description: "On Friday, healthcare stocks showed significant intraday volatility. Gainers included Quoin Pharmaceuticals (+24.6%), Aethlon Medical (+21.19%), and Xtant Medical Holdings (+15.93%). Conversely, major losers were BioXcel Therapeutics (-76.5%), BioAtla (-45.55%), and Propanc Biopharma (-40.81%). The session highlighted sharp price movements across various small-cap medical companies."
datetime: "2026-08-28T17:05:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297357269.md)
  - [en](https://longbridge.com/en/news/297357269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297357269.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's Intraday Session

### Gainers

-   **Quoin Pharmaceuticals** (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million.
-   **Aethlon Medical** (NASDAQ:AEMD) shares moved upwards by 21.19% to $2.63. The company's market cap stands at $1.5 million.
-   **Xtant Medical Holdings** (AMEX:XTNT) shares increased by 15.93% to $0.38. The market value of their outstanding shares is at $46.2 million.
-   **Femasys** (NASDAQ:FEMY) stock increased by 15.23% to $3.21. The company's market cap stands at $23.3 million.
-   **Rafael Holdings** (NYSE:RFL) shares moved upwards by 12.57% to $2.67. The market value of their outstanding shares is at $123.2 million.
-   **Bristol-Myers Squibb Company Celegne Contingent Value Rights** (NYSE:CELGR) stock moved upwards by 8.9% to $0.12.

### Losers

-   **BioXcel Therapeutics** (NASDAQ:BTAI) shares decreased by 76.5% to $0.17 during Friday's regular session. The market value of their outstanding shares is at $22.5 million.
-   **BioAtla** (NASDAQ:BCAB) stock fell 45.55% to $1.71. The company's market cap stands at $5.2 million.
-   **Propanc Biopharma** (NASDAQ:PPCB) shares fell 40.81% to $1.32. The market value of their outstanding shares is at $5.0 million.
-   **Profusa** (NASDAQ:PFSA) shares decreased by 29.13% to $3.0. The company's market cap stands at $2.5 million.
-   **Celularity** (NASDAQ:CELU) shares declined by 26.2% to $1.55. The market value of their outstanding shares is at $59.8 million.
-   **Beyond Air** (NASDAQ:XAIR) stock declined by 18.6% to $4.64. The company's market cap stands at $5.6 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [QNRX.US](https://longbridge.com/en/quote/QNRX.US.md)
- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)
- [AEMD.US](https://longbridge.com/en/quote/AEMD.US.md)
- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)
- [BCAB.US](https://longbridge.com/en/quote/BCAB.US.md)
- [BTAI.US](https://longbridge.com/en/quote/BTAI.US.md)
- [BTAIQ.US](https://longbridge.com/en/quote/BTAIQ.US.md)
- [FEMY.US](https://longbridge.com/en/quote/FEMY.US.md)
- [RFL.US](https://longbridge.com/en/quote/RFL.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [CELU.US](https://longbridge.com/en/quote/CELU.US.md)
- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)
- [74907L409.US](https://longbridge.com/en/quote/74907L409.US.md)
- [PPCBD.US](https://longbridge.com/en/quote/PPCBD.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)
- [CELUW.US](https://longbridge.com/en/quote/CELUW.US.md)

## Related News & Research

- [Propanc Biopharma Reports Preclinical Data With Prp & Prp Plus Tgf-Β Inhibitor On Tgf-Β Pathway In Pancreatic Cancer](https://longbridge.com/en/news/303966448.md)
- [Propanc Biopharma reports PRP reduces pancreatic cancer cell growth in preclinical study](https://longbridge.com/en/news/303964539.md)
- [Propanc Advances Assay Development for PPC-001 Phase 1b Trial in Up to 50 Cancer Patients](https://longbridge.com/en/news/303748685.md)
- [Propanc Biopharma plans Phase 1b PRP trial in up to 50 advanced cancer patients](https://longbridge.com/en/news/303394119.md)
- [Propanc Biopharma Plans Phase 1b Trial of PRP in Advanced Solid Tumors for Q1 2027](https://longbridge.com/en/news/303083656.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**